A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subjects
Dose Escalation Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 After Intravenous Infusion Administration in Healthy Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yuanyuan Huang, M.M
- Phone Number: +0518-82342973
- Email: yuanyuan.huang@hengrui.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410013
- The Third XIANGYA Hospital of Central South University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male and female subjects aged 18 to 45 years;
- Conform to the ASA I Physical Status Classification;
- Male subjects weighed ≥ 50kg, female subjects weighed ≥ 45kg, and body mass index (BMI) was in the range of 19.0~26.0 kg/m2 (inclusive);
- No pregnancy plan for the next 3 months and voluntary use of highly effective contraception during the trial;
- Able and willing to provide a written informed consent.
Exclusion Criteria:
- Subjects with any clinically serious disease, such as circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic abnormalities, that may affect the pharmacokinetic characteristics or safety evaluation of the investigational drug as determined by the investigator;
- Subjects with neuromuscular disease;
- Subjects with a history of anatomic airway abnormalities;
- Subjects with any known allergy history or specific allergic diseases (e.g., allergic asthma, urticaria, eczema, etc.);
- Subjects who underwent major surgery within 3 months prior to screening;
- Subjects who underwent surgery that could significantly affect the pharmacokinetic characteristics or safety evaluation of the investigational drug, or who planned to undergo surgery during the study period;
- Subjects who received antihistamines or antidepressants within 3 months prior to screening;
- Subjects who used any drug that inhibits or induces liver metabolism of drugs (e.g., inducers - barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole; Inhibitors - SSRI antidepressants, cimetidine, diltiazem, macrolides, nitroimidazoles, sedatives and hypnotics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration;
- Subjects who had used any medication within 14 days prior to administration;
- Subjects who took other investigational drugs or used investigational devices within 3 months prior to the screening, or who planned to participate in other clinical trials during the study period;
- Subjects who donated blood or suffered massive blood loss of >= 400 mL (except for physiological blood loss in women), received blood transfusions or used blood products within 3 months prior to the study, or planned to donate blood during the study period or within 1 month after finishing the study;
- Subjects who smoked more than 5 cigarettes per day on average within 3 months prior to the study, or who could not quit smoking during the study period;
- Subjects had a history of alcohol abuse within 3 months prior to the study, i.e., an average of more than 14 units of alcohol per week;
- Subjects who consumed excessive amounts of tea, coffee, and caffeinated beverages within 3 months prior to the study;
- Subjects who consumed special diet (e.g., grapefruit, grapefruit juice or food/drink containing grapefruit juice, chocolate, tobacco, alcohol, caffeine, etc.) within 48 hours before administration;
- Subjects who have special requirements for diet and cannot comply with a unified diet;
- The results of various examinations during the screening period were judged by the research doctor to be clinically significant abnormal;
- Subjects who have one or more positive test results for hepatitis B virus surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and Treponema pallidum antibody;
- Women who are pregnant or have a positive pregnancy test, or during breast-feeding;
- Subjects with positive alcohol expiratory test results;
- Subjects with positive smoking test results;
- Not suitable to be included in the study for other reasons as considered by investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment group A1
HRS3797 for injection
|
HRS3797 for injection, low dose
HRS3797 for injection, medium dose
HRS3797 for injection, high dose
|
|
Experimental: Treatment group A2
HRS3797 for injection
|
HRS3797 for injection, low dose
HRS3797 for injection, medium dose
HRS3797 for injection, high dose
|
|
Experimental: Treatment group B1
HRS3797 for injection
|
HRS3797 for injection, low dose
HRS3797 for injection, medium dose
HRS3797 for injection, high dose
|
|
Experimental: Treatment group B2
HRS3797 for injection
|
HRS3797 for injection, low dose
HRS3797 for injection, medium dose
HRS3797 for injection, high dose
|
|
Experimental: Treatment group C1
HRS3797 for injection
|
HRS3797 for injection, low dose
HRS3797 for injection, medium dose
HRS3797 for injection, high dose
|
|
Experimental: Treatment group C2
HRS3797 for injection
|
HRS3797 for injection, low dose
HRS3797 for injection, medium dose
HRS3797 for injection, high dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum T1 Suppression
Time Frame: 0 minute to full neuromuscular recovery after administration
|
0 minute to full neuromuscular recovery after administration
|
|
Time to Maximum T1 Suppression
Time Frame: 0 minute to full neuromuscular recovery after administration
|
0 minute to full neuromuscular recovery after administration
|
|
The onset of neuromuscular block
Time Frame: 0 minute to full neuromuscular recovery after administration
|
0 minute to full neuromuscular recovery after administration
|
|
The duration of neuromuscular block
Time Frame: 0 minute to full neuromuscular recovery after administration
|
0 minute to full neuromuscular recovery after administration
|
|
The recovery rate of neuromuscular block
Time Frame: 0 minute to full neuromuscular recovery after administration
|
0 minute to full neuromuscular recovery after administration
|
|
Pharmacokinetic parameter of HRS3797: Cmax
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
Pharmacokinetic parameter of HRS3797: AUC0-t
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
Pharmacokinetic parameter of HRS3797: AUC0-∞
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
Pharmacokinetic parameter of HRS3797: Tmax
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
Pharmacokinetic parameter of HRS3797: t1/2z
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
Pharmacokinetic parameter of HRS3797: CLz
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
Pharmacokinetic parameter of HRS3797: Vz
Time Frame: 0 minute to 1.5 hour after administration
|
0 minute to 1.5 hour after administration
|
|
The change of plasma histamine concentration from baseline
Time Frame: 0 minute to 1 hour after administration
|
0 minute to 1 hour after administration
|
|
The incidence and severity of adverse events/serious adverse events
Time Frame: from ICF signing date to day 28
|
from ICF signing date to day 28
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The ED95 dosage
Time Frame: 0 minute to full neuromuscular recovery after administration
|
0 minute to full neuromuscular recovery after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- HRS3797-103
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.